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EDITORIAL
Overall lung cancer survival rates are mainly driven by the proportion of patients under-going curative surgery. The resection rate usually includes all patients operated upon 
and is thus strongly related to survival. However, although resection rate is increasingly 
more emphasized as a quality indicator, it is not an indicator of appropriate selection of 
patients to lifesaving treatment. The term resection rate is not even properly defined, and 
there is no standard for how it should be reported. Therefore, one should be cautious in 
comparing resection rates that may differ by several percentage points depending on their 
context. For example, whether small-cell lung cancer (SCLC) and other less frequent his-
tological subgroups are excluded, whether cases based on death certificate only (DCO) are 
included, whether only curative resections are counted, and whether histologically uncon-
firmed cases are a part of the denominator. A definition should also account for what 
should be regarded as a resection in terms of completeness of tumor removal. Should syn-
chronous tumors be counted separately or together? Further, overestimation might occur 
if the completeness of the cancer registration in the population under investigation is poor.
The series from Iceland reported in this issue of Journal of Thoracic Oncology high-
lights the resection rate, which is relatively high, at 26.4% for a whole nation.1 One should, 
however, be aware that 306 cases without histological diagnosis were excluded, along 
with SCLC, carcinoids, sarcomas, and carcinoma in situ. If those without tissue diagnosis 
were included, the resection rate would be 22.0%, which is still an optimistic number. The 
authors should be praised for putting resection rates on the agenda of research. Several 
studies have previously reported national resection rates, but there has been too little atten-
tion, research, and knowledge devoted to this very important indicator. In England, the 
median national rate was 9% between 2004 and 2006, excluding from the denominator 
SCLC cases and cases reported from DCOs.2 Denmark’s latest results were 16.0% for 
2007, probably including SCLC but without information on which selection criteria were 
used.3 For older reports on national resection rates, Wilkin et al.4 have summarized a dozen 
European countries in a benchmark report from 2008. In Norway, we recently found a rate 
of 19.1% including SCLC and 22.5% excluding SCLC, while excluding DCOs for both.5
What the optimal resection rate for lung cancer is has never before been properly 
investigated. We also lack evidence based research to support recommendations for what 
range one should aim for. Laroche6 has been quoted to set the standard for limits in the 
United Kingdom at 20%. In Denmark, 25% is the goal.3 When Torsteinsson et al. report 
their national results with high quality (complete) data and good survival of patients, they 
contribute to empirical knowledge of what resection rates should be at a national level. 
They can present a reliable denominator because registration of cancer cases is considered 
complete in Iceland with the country’s high quality national registry.
Why is a small country such as Iceland performing so well? On average, only 27 
patients had a resection each year in Iceland, and surgical treatment is certainly central-
ized. We can only speculate; but at the same time as this is a national material, it is also a 
report from a single center as only one hospital performed thoracic surgery in Iceland. In 
other countries, resection rates vary widely among different regions. In England, regional 
resection rates vary between 3% and 18%;2 in Denmark, rates vary between 13% and 24%;3 
and in Ireland, the rates varied between 8% and 16% between 1998 and 2001.7 The largest 
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span has been observed in Norway, including SCLC cases and 
those diagnosed before death, where the biennial rate varied 
from 7% and 31% among 19 counties in three periods between 
1994 and 2007.5
The explanation for Iceland’s numbers could be regional 
variation but,  nevertheless, the results have been stable over 
many years. Also, the population in Iceland seems to be com-
parable to that of other European countries in terms of baseline 
characteristics. In accordance with encouraging results from 
England, where great efforts have been made to increase the 
poor resection rates, patients in Iceland had already benefited 
from multidisciplinary team meetings for many years through-
out the whole study period. The fact that only six surgeons 
were involved is probably also a positive contributing factor.
From the results of resection rates, survival, postopera-
tive mortality, and complication rates, one can read that much 
has been done correctly for lung cancer patients on the Saga 
island.1 We are presented with an extremely low postoperative 
mortality of 1.0% in a small nation. Internationally, few coun-
tries can document better results. Only one report from Japan 
has previously demonstrated a lower rate of 0.6%.8
Overall 5-year crude survival in Iceland is 11% and 13% 
for men and women, respectively, in the period 1997–2006 
(personal communication, The Icelandic Cancer Registry). 
This is a confirmation that Iceland is at the top among 
European countries regarding long-term survival.9 The favor-
able survival rate in Iceland should be viewed in the light of 
focus on surgery, and both inclusion to treatment and care for 
the patients. The survival for resected patients is reported from 
Iceland both according to the previous (6th) and the relatively 
new and current (7th) edition of the Tumor, Node, Metastasis 
staging system. Not unexpectedly, long-term survival is higher 
in stages I and II according to the latter version. How classifi-
cation with the new system influences the ability to select the 
right candidates for surgery remains to be seen. For example, 
whether the downstaging of patients with multiple tumors in 
one lobe from T4 to T3 leads to more resections. Population-
based registries such as that of Iceland may play a role in the 
follow-up of this question.
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